HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: PROMIS-29 IN THE SEAVUE STUDY

Matthieu Allez  1     James D. Lewis  2     Peter Irving  3     Timothy Hoops  4     James Izanec  4     Tony Ma  5     Zhijie Ding     Erik Muser     Christopher Gasink     Remo Panaccione     Edward V. Loftus Jr     Bruce E. Sands     Silvio Danese    
1 Université de Paris,Paris,France
2 Perelman School of Medicine at the University of Pennsylvania,Philadelphia,United States
3 Guy’s and Saint Thomas’ Hospitals NHS Trust,London,United Kingdom
4 Janssen Scientific Affairs, LLC,Horsham,United States
5 Janssen Scientific Affairs, LLC,Hor

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing